Loading
NASDAQHealthcareBiotechnology
Latest quote
$37.39
+$1.95 · +5.50%
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Previous close
$37.39
+$1.95 · +5.50%
Regular session · ET · Market data may be delayed.
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Day range
Current $37.39
52-week range
Current $37.39
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
40
Expensive
Sentiment
61
Bullish
Risk
48
Elevated Risk
Momentum
39
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Day range
Current $37.39
52-week range
Current $37.39
| Metric (USD) | FY2025 |
|---|---|
| Research and development | 76.61M USD |
| Selling, general, and administrative | 14.68M USD |
| Operating expenses | 91.29M USD |
| Interest income | 6.18M USD |
| Depreciation and amortization | 42K USD |
| Operating income | −91.29M USD |
| Net income | −85.2M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$60.00
60.47% upsidePrice history unavailable
High $80.00Average $60.00Low $51.00Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI15.39M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM15.12M0.02%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF5.56M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO3.88M0.03%14.58B USD0.24%$377.54+0.12%
Schwab U.S. Small-Cap ETFSCHA2.83M0.01%22.56B USD0.03%$34.55+1.01%
Vanguard Russell 2000 ETFVTWO2.77M0.02%17.4B USD0.06%$119.62+0.25%
T. Rowe Price Small-Mid Cap ETFTMSL2.47M0.08%2.97B USD0.55%$42.78+0.26%
iShares Russell 2000 Value ETFIWN1.71M0.01%14.47B USD0.24%$224.62+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOT. Rowe Price Small-Mid Cap ETFTMSLiShares Russell 2000 Value ETFIWNAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
